source
- Novartis reports Phase 3 success for MS pill remibrutinib, beats Aubagio and shows no liver safety issuesNovartis announced that its BTK inhibitor remibrutinib met primary endpoints in two Phase 3 trials in patients with relapsing multiple sclerosis. The studies showed the drug reduced annualized rel…
- Novartis reports positive multiple sclerosis results with its BTK inhibitorNovartis announced that its BTK inhibitor has shown a positive outcome in a multiple sclerosis study, marking a notable advance for the company in this therapeutic area. The result highlights the…